Patent Application
20220016144
The present invention concerns a stable aqueous composition comprising oligosaccharides having a glucose unit at the reducing end and characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3. The invention also relate to the use of such aqueous composition as a milk fortifier or supplement for infants, in particular infants who were born by C-section, who were born preterm, or who are small for gestational age and/or who had a low or very low weight at birth (LWB or VLBW). The invention further relates to a method for preventing isomerization of the glucose unit at the reducing end of such oligosaccharides during heat treatment in aqueous compositions.
Mother's milk is recommended for all infants. However, in some cases breast feeding is inadequate or unsuccessful for medical reasons or the mother chooses not to breast feed. Infant formulae have been developed for these situations. Fortifiers and supplements have also been developed to enrich mother's milk or infant formula with specific ingredients.
The importance of oligosaccharides which are contained in human breast milk (human milk oligosaccharides, HMOs) is well recognized in the scientific community as being key to support digestive health, gut and/or mucosal maturation, and/or immune maturation in infants. Accordingly, where the feeding of an infant is deprived of such nutrients (as the infant receives infant formulas not containing HMOs) or where the amount of HMOs in the human breast milk or formula the infant receives are not adequate to his needs, a composition providing HMOs in the form of a supplement to be administered to the infant or dissolved into his feeding would be desiderable.
In particular, an aqueous liquid composition comprising HMOs would be needed.
Liquid aqueous compositions for enteral nutrition need to be microbiologically safe.
Often oligosaccharides cannot be concentrated sufficiently in an aqueous solution to reach a microbiologically safe low water activity, because the resulting high density would not allow easy feeding application due to high viscosity and because many oligosaccharides would start to crystallize in a high-density solution.
To address the problem, aseptic filling or sterilization by retorting may be implemented but such procedures provoke during heat treatment isomerization of the reducing terminal monosaccharides of oligosaccharides.
Accordingly, a liquid aqueous composition comprising HMO would be needed that does not incur the isomerization of the reducing terminal monosaccharides of oligosaccharides when subject to heat treatments.
Additionally, storage often alters the oligosaccharide structure and function and consequently the quality of oligosaccharide products in aqueous compositions over time.
Accordingly, a liquid aqueous composition comprising HMO would be needed which shows stability for the oligosaccharides over time.
Furthermore, a liquid aqueous composition comprising HMOs should be characterized by respecting the infant physiology when such composition is administered, either as a stand alone supplement or dissolved in human breast milk.
For example, a too acidic pH of the aqueous composition would not be adapted to administration to infants. This aspect is of particular relevance when the recipient of the aqueous liquid composition is an infant who was born preterm, or who is small for gestational age and/or who had a low or very low weight at birth (LWB or VLBW).
Accordingly, a liquid aqueous composition comprising HMO would be needed which would not alter the infant physiology such as the acid-base balance and to avoid acidosis when such composition is administered.
Accordingly, it is an object of the present invention to identify a solution to prevent isomerization of the reducing terminal monosaccharides of oligosaccharides in aqueous compositions. Additionally, it is a further object of the present invention to prevent degradation of oligosaccharides in aqueous compositions over storage. Additionally, it is another object of the present invention to provide a liquid aqueous composition comprising HMO which would not alter the infant physiology when such composition is administered.
The inventors surprisingly found that mild acidification at a pH which may range from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, of an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end stabilized such oligosaccharide against isomerization. Very surprisingly, mild acidification also prevented hydrolysis during storage.
Accordingly, in one aspect the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end and being characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another aspect, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end and being characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, for use as a milk fortifier or supplement for infants, in particular infants who were by C-section, who were born preterm, or who are small for gestational age and/or who had a low or very low weight at birth (LWB or VLBW).
In another aspect, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end and being characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, for use in supporting digestive health, gut and/or mucosal maturation, and/or immune maturation in infants, in particular infants who were born by C-section, or were born preterm, or who are small for gestational age and/or who had a low or very low weight at birth (LWB or VLBW).
In a further aspect, the present invention also provides for the use of an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end and being characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, as a milk fortifier or supplement for infants, in particular infants who were born by C-section or were born preterm, or who are small for gestational age and/or who had a low or very low weight at birth (LWB or VLBW).
In an additional aspect, the present invention provides for a method for preventing isomerization in aqueous compositions during heat treatment of oligosaccharides having a glucose unit at the reducing end such method comprising:
In another aspect, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end and being characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, which is packed in a single dose unit.
Additional features and advantages of the present invention are described in, and will be apparent from, the description of the embodiments which are set out below with reference to the drawings in which:
Within the context of the present invention, the term “monosaccharide” indicates carbohydrates containing from 3 to 6 carbon atoms. They can be polyhydroxy aldehydes or polyhydroxyketones depending on whether they comprise either an aldehyde or a ketone group, along with —OH substituted carbons in a chain. Polyhydroxy aldehydes are called “aldoses”. Polyhydroxyketones are called “Ketoses”. Non limiting examples of 6 carbon monosaccharide (hexose) are: allose, altrose, glucose, mannose, gulose, idose, galactose, talose, psicose, fructose, sorbose and tagatose. Non limiting examples of 5 carbon monosaccharide (pentose) are: ribose, arabinose, xylose, lyxose, ribulose and xylulose.
Within the context of the present invention, the term “oligosaccharide” indicates a linear or branched saccharide polymer containing a small number (typically two to ten) of simple sugars (5 or 6 membered monosaccharides as above defined).
Within the context of the present invention, the term “reducing end” for the oligosaccharide unit identifies the terminal monosaccharide with a free anomeric carbon that is not involved in a glycosidic link.
Within the context of the present invention, the term “anomeric carbon” identifies the carbonyl carbon of a monosaccharide in its acyclic form. Depending on the position assumed by —OH group attached to the anomeric carbon when the monosaccharide is in cyclic from (chair conformation), the configuration of such carbon is defined as being a (alpha) or β (beta) if the group —OH is axial or equatorial, respectively.
Within the context of the present invention, the term “oligosaccharide having a glucose unit at the reducing end” identifies an oligosaccharide molecule as above defined which presents a glucose unit at the reducing end. Non-limiting examples of such oligosaccharides are:
Within the context of the present invention, the expressions “fucosylated oligosaccharides comprising a 2′-fucosyl-epitope” and “2-fucosylated oligosaccharides” encompass fucosylated oligosaccharides with a certain homology of form since they contain a 2′-fucosyl-epitope, therefore a certain homology of function can be expected.
Within the context of the present invention, the expression “at least one fucosylated oligosaccharide” and “at least one N-acetylated oligosaccharide” means “at least one type of fucosylated oligosaccharide” and “at least one type of N-acetylated oligosaccharide”.
Within the context of the present invention, the term “aqueous compositions” identifies liquid compositions which may be solutions and/or dispersions of the at least one oligosaccharide in an aqueous mean.
Within the context of the present invention, the term “isomerization” indicates the process where the tridimensional arrangement of atoms in one molecule changes, producing a new molecule with the same number of atoms but with a different structure.
Within the context of the present invention, the term “pH modulator” indicates a substance which is capable of affecting (i.e. decreasing, increasing or stabilizing) the pH of an aqueous solution. Non-limiting examples of pH modulators are strong and mild acids (organic or inorganic), acidic oligosaccharides, strong and mild bases (organic or inorganic) as well as buffers (organic or inorganic). Non limiting examples of organic acids are: Citric acid, Phosphoric acid, Lactic acid and sialic acid. Non limiting examples of inorganic bases are: potassium hydroxide (KOH) and sodium hydroxyde (NaOH). Non limiting examples of acidic oligosaccharides are sialic acid [N-acetyl-neuraminic acid (Neu5Ac)] or uronic acids (glucuronic acid, galacturonic acid).
Within the context of the present invention, the term “buffer” or “buffering agent” indicates a substance which is capable of stabilizing the pH of an aqueous solution within a certain narrow pH range. Buffering agents may be combined and/or dissolved in water to provide a buffering solution which are also comprised within the scope of the term “buffer” and/or “buffering agent”. Non-limiting examples of buffering agents are: citric acid, acetic acid, phosphate salts (sodium or potassium). Non limiting examples of buffering solutions are: Phosphate buffer (based on 2 phosphates salts, for example sodium phosphate monobasic and sodium phosphate dibasic) and citrate-phosphate buffer (for example Mcllvaine buffer—based on citric acid and disodiumphosphate)
Within the context of the present invention, the term “fortifier” refers to a composition which comprises one or more nutrients having a nutritional benefit for infants.
By the term “milk fortifier”, it is meant any composition used to fortify or supplement either human breast milk, infant formula, growing-up milk or human breast milk fortified with other nutrients. Accordingly, the human milk fortifier of the present invention can be administered after dissolution in human breast milk, infant formula, growing-up milk or human breast milk fortified with other nutrients or otherwise it can be administered as a stand alone composition.
When administered as a stand-alone composition, the human milk fortifier of the present invention can be also identified as being a “supplement”. In one embodiment, the milk fortifier of the present invention is a supplement.
By the term “human milk fortifier”, it is meant any composition used to fortify or supplement human breast milk, or human breast milk fortified with other nutrients.
Within the context of the present invention, the expression “composition having a pH ranging from value X to value Y” identifies compositions having a pH range which has one specified value within the indicated range (extremes X and Y of the range being included) as well as compositions having a pH which varies within the indicated range (extremes X and Y of the range being included).
In one embodiment, the aqueous composition according to the present invention comprises two or more oligosaccharides having a glucose unit at the reducing end.
In one embodiment, the aqueous composition according to the present invention comprises two oligosaccharides having a glucose unit at the reducing end.
In one embodiment, the aqueous composition according to the present invention comprises three oligosaccharides having a glucose unit at the reducing end.
In one embodiment, the aqueous composition according to the present invention comprises five oligosaccharides having a glucose unit at the reducing end.
In one embodiment, the aqueous composition according to the present invention comprises six oligosaccharides having a glucose unit at the reducing end.
In one embodiment, the aqueous composition according to the present invention comprises seven oligosaccharides having a glucose unit at the reducing end.
In one embodiment, in the aqueous composition according to the present invention, the at least one oligosaccharide having a glucose unit at the reducing end is selected in the group consisting of: 2′-FL, 3′-SL, 6′-SL, DFL, LNnT, LNT and 3-FL.
In another embodiment, in the aqueous composition according to the present invention, the at least one oligosaccharide having a glucose unit at the reducing end is selected in the group consisting of: 2′-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT.
In one embodiment, the aqueous composition according to the present invention comprises two oligosaccharides having a glucose unit at the reducing end and being selected in the group consisting of: 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT, for example being 2′-FL and LNnT.
In one embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL and LNnT in a ratio of 10:1. In another embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL and LNnT in a ratio of 2:1.
In one embodiment, the aqueous composition according to the present invention comprises three oligosaccharides having a glucose unit at the reducing end and being selected in the group consisting of: 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT.
In one embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL, DFL and LNT in a ratio of 10:1:3.33.
In one embodiment, the aqueous composition according to the present invention comprises five oligosaccharides having a glucose unit at the reducing end and being selected in the group consisting of: 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT, for example being 2′-FL, 3′-SL, 6′-SL, DFL, and LNT.
In another embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL, DFL, LNT, 6′-SL and 3′-SL in a ratio of 10:1:3.33:1.7:1.2.
In one embodiment, the aqueous composition according to the present invention comprises six oligosaccharides having a glucose unit at the reducing end and being selected in the group consisting of: 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT, for example being 2′-FL, 3′-SL, 6′-SL, DFL, and LNT
In one embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL, DFL, LNT, LNnT, 6′-SL and 3′-SL in a ratio of 10:1:3.33:1.1:1.7:1.2.
In one embodiment, the aqueous composition according to the present invention comprises seven oligosaccharides having a glucose unit at the reducing end and being 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT.
In another embodiment, the present invention provides an aqueous composition as above defined which comprises 2′-FL, DFL, 3-FL, LNT, LNnT, 6′-SL and 3′-SL in a ratio of 10:1:2.5:3.33:1.1:1.7:1.2.
In one embodiment, the aqueous composition according to the invention has a pH ranging from 5.5 to 6.5.
In a further embodiment, the aqueous composition according to the invention has a pH ranging from 5.8 to 6.3.
In another embodiment, the aqueous composition according to the invention has a pH ranging from 5.9 to 6.2.
In another embodiment, the aqueous composition according to the invention has a pH around 6.
As it can be understood by the skilled person, the pH of the aqueous composition may be also affected by the intrinsic acidity/basicity of the ingredients of the composition and may be then modulated by the use of an appropriate pH modulator.
For example, human milk oligosaccharides which are added in the crystalline form may bring a contribution in the direction of an acidic pH if the material contain residual acetic acid from crystallization process. Such acidic pH may be adjusted and stabilized within the pH range according to the invention via the use of appropriate pH modulators.
In one embodiment, the aqueous composition according to the invention has a pH ranging from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, which is achieved via the addition of one or more pH modulators.
In another embodiment, the pH modulator is an inorganic base, for example KOH or NaOH.
In one embodiment, the pH modulator also consists of or comprises a buffering agent, for example phosphate buffer, or citrate-phosphate buffer (also known as Mcllvaine buffer, based on a mixture of citric acid and disodiumphosphate).
As it can be inferred from the data reported in
Accordingly, the option of including a buffering agent in the composition offers the additional advantage of allowing the pH to remain stable over time.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL and LNnT.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL and LNT.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 4.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the at least one oligosaccharide.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharidse.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL and LNnT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharidse.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL and LNT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end at a concentration ranging from 5 to 50% w/w of the composition.
In another embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition.
In a still further embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end at a concentration ranging from 10 to 30% w/w of the composition.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL and LNnT.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL and LNT.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 4.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharide having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the at least one oligosaccharide.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In one embodiment, the present invention provides an aqueous composition comprising at least one oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharidse.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In another embodiment, the present invention provides an aqueous composition comprising two oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL and LNnT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharidse.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a further embodiment, the present invention provides an aqueous composition comprising five oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL and LNT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharide.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
In a still further embodiment, the present invention provides an aqueous composition comprising six oligosaccharides having a glucose unit at the reducing end at a concentration ranging from 8 to 35% w/w of the composition, a pH modulator, a buffering agent and wherein the pH of such aqueous composition ranges from 5.5 to 6.5, for example from 5.8 to 6.3 or from 5.9 to 6.2, the oligosaccharides are 2′-FL, 3′-SL, 6′-SL, DFL, LNnT and LNT and the composition doesn't comprise other nutrients in addition to the oligosaccharides.
By having a liquid form, aqueous compositions according to the present invention present some particular benefits. For example, they may be more conveniently packed to deliver calibrated drops of a certain weight or volume.
In some embodiment, aqueous compositions of the present invention may be packed in single doses in such a way that calibrated drops of a certain weight or volume are delivered while avoiding contamination of the remaining liquid due to manipulation and subsequent uses.
In one embodiment, the liquid aqueous composition according to the present invention is presented in single dose units which are packed in plastic material. In one embodiment, such plastic material is flexible and squeezable. In one embodiment, such plastic material may be polypropylene (PP) or Polyethylene (PE). In one embodiment, polypropylene may be low density (LD PE) or high density (HD PE). In addition, aqueous compositions are easy to mix with compositions to be fortified, whereas the powder ones can, in some cases, form lumps.
In one embodiment, the aqueous composition according to the present invention and above described is a supplement. In such embodiment, the aqueous composition of the invention is administered as a stand alone composition. In such embodiment, the aqueous composition of the invention is administered as a stand alone composition and is packed in single doses.
In one embodiment, the aqueous composition according to the present invention is a milk fortifier. In such embodiment, the aqueous composition of the invention may be packed in single doses.
An oligosaccharide (laminaritriose) internal standard is mixed with the oligosaccharide solution and the oligosaccharides are fluorescently labelled by reaction of the 2-anthranilic acid amide (2AB) with the OS reducing end via formation of a Schiff base. The double bond is then reduced by reaction with sodium cyanoborohydride to give a stable OS-2AB derivative.
Labelled samples are diluted with acetonitrile (ACN) prior to injection on an ultra high performance liquid chromatography (UHPLC) system equipped with hydrophilic interaction liquid chromatography (HILIC) trapping and analytical columns. Labelled OS are detected by a fluorimeter.
Oligosaccharide concentrations are determined from a standard curve using the relative response of the oligosaccharide (OS) to the internal standard (Laminaritriose).
Oligosaccharides 2′Fucosyllactose (2′FL) and Lacto-N-neotetraose (LNnT) were mixed in a 2:1 ratio (w/w) and dissolved in water to a final concentration of 10% (w/v). Solutions were acidified to pH 6 with citric acid and subjected to heat treatment (UHT) followed by aseptic filling of small monodose bottles. Solutions were analysed before and after filling of bottles as well as after different times of storage at 37° C. (accelerated storage condition).
Analysis was done by HPLC using a TSK gel Amide-80 (150 mm×4.6 mm, particle size: 3 μm) column and detection via a charged aerosol detector. For the fructose isomers of the added 2′FL and LNnT as well as for their degradation products (fucose, lactose and Lacto-N-triose) quantification was done using the relative response of the oligosaccharide to a standard curve. Fucose, Lactose, 2FL, LNnT, 2′-fucosyl-lactulose and LNnT fructose isomer were used as standards. Lacto-N-triose contents were calculated with the calibration curve of LNnT. Results are reported in
The results indicate that at pH 6, very limited formation of such degradation and/or isomerization products is observed, either at aseptic filling or during storage under accelerated conditions, thus showing the stability of the aqueous solution of the invention under the tested conditions.
Oligosaccharides 2′Fucosyllactose (2′FL) and Lacto-N-neotetraose (LNnT) were mixed in a 10:1 ratio (w/w) and dissolved in water to a final concentration of 10% (w/v). Out of this solution, three samples were generated respectively having pH 6 and 7 (by addition of KOH) Such samples were subjected to heat treatment (UHT) followed by aseptic filling of small monodose bottles. Solutions at different pHs were analysed before and after filling of bottles as well as after different times of storage at room temperature (21-26° C.). Analysis was done by HPLC using a TSK gel Amide-80 (150 mm×4.6 mm, particle size: 3 μm) column and detection via a charged aerosol detector. F or 2′FL (
The results indicate that at pH 7 2FL undergoes significant transformation as it appears from the decreased levels at asepting filling and over time
At pH 6, the situation is considerably different. Firstly, 2FL and LNnT amounts appear to be much more stable (
Oligosaccharides 2′Fucosyllactose (2′FL) and Lacto-N-neotetraose (LNnT) were mixed in a 10:1 ratio (w/w) and dissolved in buffered water (phosphate buffer as before defined) to a final concentration of 10% (w/v). Solution is submitted to a sterile filtration and filled in plastic monodose unit. Resulting pH of the solution before and after sterile filtration was around 6.
0.91 of LNnT and 9.09 g of 2′-FL have been dissolved in water (to a final volume of 100 ml), to a final concentration of 10 g/I (10% w/v).
From the obtained solution 2 aliquots have been obtained (HMO's solutions). In one aliquot the pH has been adjust to 5 using a citric acid solution (10% w/w). In another aliquot pH has been adjusted to 6 using KOH solution (10% w/w).
4 g of the above mentioned HMO's solutions have been added to 2 samples of human breast milk (20 g each). The initial pH of the pure breastmilk has been measured and recorded as being 7.3.
The final pH of the samples obtained by dissolution of the HMO's solutions in human breast milk has been measured, data are shown in the below table 1.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 18212616.9 | Dec 2018 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/084308 | 12/10/2019 | WO | 00 |
